Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zecheng Yang

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Cell Reports. Medicine|February 18, 2026
Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancerZecheng Yang, Madelaine S Theardy, Shuaitong Chen, et al.
Cell Reports. Medicine|July 27, 2025
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMadelaine S Theardy, Mitsunobu Takeda, Alexey Sorokin, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMitsunobu Takeda, Madelaine S Theardy, Alexey Sorokin, et al.
Cancer Research|September 18, 2025
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic CancerYongkun Wei, Minghui Liu, Er-Yen Yen, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Cell Reports. Medicine|February 18, 2026
Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancerZecheng Yang, Madelaine S Theardy, Shuaitong Chen, et al.
Cell Reports. Medicine|July 27, 2025
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMadelaine S Theardy, Mitsunobu Takeda, Alexey Sorokin, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMitsunobu Takeda, Madelaine S Theardy, Alexey Sorokin, et al.
Cancer Research|September 18, 2025
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic CancerYongkun Wei, Minghui Liu, Er-Yen Yen, et al.
Pageof 4